🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆ Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆
Clinical Trials in Egypt / NCT07424105
Starting soon Not applicable

Effect of Optokinetic Stimulation on Spatial Neglect and Postural Stability in Patients With Stroke

NCT07424105 · tracked via the Priya Life Science Egypt tracker
Phase
Not applicable
Started
2026-02-20
Last updated
2026-02-20

Condition(s) studied

Stroke

Investigational drug(s) / intervention(s)

Optokinetic stimulationSham optokinetic stimulationTraditional therapy

Optokinetic stimulation: Patients will receive optokinetic stimulation (OKS) as an intervention for spatial neglect, based on observing moving visual stimuli to promote visual scanning of the neglected hemispace. With the patient properly positioned, the physiotherapist will apply virtual reality glasses supported by a mobile device displaying pre-prepared OKS videos. The videos will show vertical bars moving leftward at a fixed speed of 1 cm/s, with random color changes to maintain attention. Patients will be instructed to report each color change. OKS will be delivered in five 4-minute bouts separated by 1-minute rest intervals, totaling 20 minutes per session.

Sham optokinetic stimulation: A static image consisting of black-and-white vertical bars will be projected for patients in this group. The bars will undergo random color changes similar to those used in the intervention group; however, no movement will be present.

Traditional therapy: All participants in both groups will receive a selected physical therapy program for 30 min per session to enhance balance for 10 weeks.

Study summary

The purpose of this study is to investigate the efficacy of optokinetic stimulation in stroke patients by examining its effects on spatial neglect, static balance, dynamic balance, and weight-bearing symmetry.

Eligibility

Sex
ALL
Min age
50 Years
Max age
65 Years
Healthy volunteers
No
Inclusion Criteria: * Patient's age ranges from 50 to 65 years referred by neurologist. * Patient's will be diagnosed as stroke in the subacute stage * Patients will suffer from spatial neglect resulting from the stroke that screened by albert's test. * Patients are medically stable and able to understand and follow instructions. Exclusion Criteria: * There is any previous neurological disability * There is general unstable conditions, history of epilepsy, cardiac pacemakers * There is sever cognitive disorder * There is visual field deficit

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Nahda University Banī Suwayf Egypt

More Cairo University trials in Egypt

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07424105 on ClinicalTrials.gov ↗ ← All trials in Egypt